ciclesonide for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
Clemency NCT04377711		RCT	ciclesonide	placebo	COVID 19 outpatients	low	197/203	inconclusive
Ezer N (CONTAIN) NCT04435795		RCT	ciclesonide	placebo	COVID 19 outpatients	some concern	108/107	inconclusive	inconclusive 25 % increase in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis